Document is current
Any future updates will be listed below
-
Authors
Han, Xuexiang https://orcid.org/0000-0003-0011-5222
Alameh, Mohamad-Gabriel
Gong, Ningqiang https://orcid.org/0000-0002-9444-8505
Xue, Lulu https://orcid.org/0000-0001-5719-1336
Ghattas, Majed https://orcid.org/0000-0001-9651-5014
Bojja, Goutham
Xu, Junchao https://orcid.org/0000-0003-0725-8111
Zhao, Gan https://orcid.org/0000-0002-8043-6036
Warzecha, Claude C. https://orcid.org/0000-0002-3659-2867
Padilla, Marshall S. https://orcid.org/0000-0003-3607-790X
El-Mayta, Rakan https://orcid.org/0000-0002-5855-233X
Dwivedi, Garima
Xu, Ying https://orcid.org/0000-0001-7341-8676
Vaughan, Andrew E. https://orcid.org/0000-0001-5740-643X
Wilson, James M. https://orcid.org/0000-0002-9630-3131
Weissman, Drew https://orcid.org/0000-0002-1501-6510
Mitchell, Michael J. https://orcid.org/0000-0002-3628-2244
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (DP2 TR002776, DP2 TR002776, DP2 TR002776, DP2 TR002776)
- License Information
-
More Information
Article History
Received: 26 October 2022
Accepted: 14 May 2024
First Online: 9 July 2024
Competing interests
: X.H. and M.J.M. are inventors on a patent filed by the Trustees of the University of Pennsylvania (US provisional patent application no. 63/589,051, filed 10 October 2023) describing the amidine-incorporated degradable lipid nanoparticle technology in this paper. In accordance with the University of Pennsylvania policies and procedures and our ethical obligations as researchers, we report that D.W. is named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins and vaccines. M.J.M., X.H., D.W. and M.-G.A. are also named on patents describing the use of lipid nanoparticles, and lipid compositions for nucleic acid delivery and vaccination. We have disclosed those interests fully to the University of Pennsylvania, and we have in place an approved plan for managing any potential conflicts arising from licensing of our patents. J.M.W. is a paid advisor to and holds equity in iECURE, Passage Bio and the Center for Breakthrough Medicines (CBM). He also holds equity in the former G2 Bio asset companies. He has sponsored research agreements with Amicus Therapeutics, CBM, Ceva Santé Animale, Elaaj Bio, FA212, Foundation for Angelman Syndrome Therapeutics, former G2 Bio asset companies, iECURE and Passage Bio, which are licensees of Penn technology. J.M.W. and C.C.W. are inventors on patents that have been licensed to various biopharmaceutical companies and for which they may receive payments. The other authors declare no competing interests.
